Related Experiment Video

Updated: Aug 12, 2026

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
06:39

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice

Published on: April 13, 2015

Do beta-adrenergic blocking agents increase coronary flow reserve?

M Billinger1, C Seiler, M Fleisch

  • 1Department of Cardiology, Swiss Cardiovascular Center, Bern, Switzerland.

Journal of the American College of Cardiology
|December 12, 2001
PubMed

Insights

Metoprolol significantly improves coronary flow velocity reserve (CFVR) in patients with coronary artery disease (CAD) by reducing vascular resistance. This beta-blocker enhances blood supply and reduces oxygen demand, benefiting CAD treatment.

Area of Science:

  • Cardiology
  • Pharmacology
  • Vascular Physiology

Background:

  • Beta-adrenergic blocking agents are crucial for treating coronary artery disease (CAD).
  • The precise mechanism of action, particularly regarding oxygen-sparing effects, requires further elucidation.
  • This study investigates metoprolol's impact on coronary flow reserve and coronary flow velocity reserve (CFVR) in CAD patients.

Purpose of the Study:

  • To determine the effect of metoprolol on coronary flow reserve and coronary flow velocity reserve (CFVR) in patients with CAD.
  • To assess changes in coronary blood flow velocity, post-ischemic CFVR, and pharmacologic CFVR before and after metoprolol administration.
  • To evaluate the impact of metoprolol on coronary vascular resistance and its relationship with CFVR.

Main Methods:

  • Coronary blood flow velocity was measured using a Doppler flow wire in 23 CAD patients.
  • Measurements included rest, post-ischemic (1-min occlusion), and post-adenosine (pharmacologic) conditions.
  • Changes were assessed before and after administering 5 mg of intravenous metoprolol, with absolute flow measured in a subgroup.

Main Results:

  • Metoprolol reduced the rate-pressure product (9.1 to 8.0 x 10(3) mm Hg/min) and coronary vascular resistance (3.4 to 2.3 mm Hg x s/cm).
  • Both pharmacologic CFVR (2.1 to 2.7) and post-ischemic CFVR (2.6 to 3.3) significantly increased post-metoprolol.
  • Post-ischemic CFVR remained significantly higher than pharmacologic CFVR, both before and after metoprolol treatment.

Conclusions:

  • Metoprolol administration leads to a significant increase in both post-ischemic and pharmacologic CFVR in CAD patients.
  • The observed increase in CFVR is attributed to a reduction in coronary vascular resistance.
  • The combined effects of increased coronary blood supply (via CFVR) and decreased myocardial oxygen demand explain metoprolol's therapeutic benefits in CAD.
Abstract

More Related Videos

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

Dynamic Assessments of Coronary Flow Reserve after Myocardial Ischemia Reperfusion in Mice05:07

Dynamic Assessments of Coronary Flow Reserve after Myocardial Ischemia Reperfusion in Mice

Published on: August 25, 2023

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...